20-Feb-2020

Merck signed an agreement to sell its allergy business Allergopharma to Dermapharm Holding SE. The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions. Since 2007, Merck has made ...

more

Liquid biopsy kits aim to improve accuracy of cancer diagnosis

19-Feb-2020

Merck announced that it has been selected by Swedish molecular diagnostics firm Elypta as the contract manufacturer for Elypta’s clinical diagnostic liquid biopsy kits. The kits analyze metabolites deregulated in several cancer types, making diagnoses more accurate. “Both small and large ...

more

28-Jan-2020

Merck announced an investment of €250million in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to biotech development and manufacturing for clinical studies. Driven by the growth of the Healthcare business sector R&D pipeline, this investment ...

more

23-Dec-2019

Merck announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, USA access to Merck’s foundational CRISPR intellectual property. Promega will use Merck’s CRISPR genome-editing technology to create research products ...

more

27-Nov-2019

Merck announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed the company’s patent application for the use of paired CRISPR nickases, bringing Merck’s number of patents to 22 worldwide. “Paired nickases represent a significant step in increasing ...

more

15-Nov-2019

Merck generated strong organic sales growth and benefited from positive foreign exchange effects in the third quarter of 2019. EBITDA pre increased even more strongly than net sales in the three-month period from July to September. Following the closing of the Versum Materials (Versum) ...

more

License to accelerate research, enable testing and development of new drugs

13-Nov-2019

Merck announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use Merck’s CRISPR genome-editing technology to create edited cell lines ...

more

31-Oct-2019

Merck and the German business journal manager magazin presented the Curious Mind Researcher Award in Berlin. Ulrike Kramm (40), a materials scientist, received the prize worth €7,500 in the category “Mobility and Energy”. Computer scientist Xiaoying Zhuang (36) was also awarded € 7,500 for her ...

more

RMB 100 million fund targets startups close to the three business sectors of Merck as well as new businesses

21-Oct-2019

Merck announced an RMB 100 million (€ 13 million) seed fund targeted at startups in China. The company also officially opened its innovation hub in Shanghai and announced plans to officially open a second innovation hub in Guangzhou in November. “Our RMB 100 million China seed fund underlines our ...

more

Acquisition of FloDesign Sonics marks next step in autologous manufacturing

11-Oct-2019

Merck announced it has acquired FloDesign Sonics, of Wilbraham, Massachusetts, USA, developer of a unique acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing. Financial details were not disclosed. “Chimeric antigen receptor T cell therapies, or CAR-T ...

more